Study On The Expression Of ER, P53 Protein And Proliferating Cell Nuclear Antigen In Human Colorectal Carcinoma And Their Clinical Significance

Objective: To investigate the expression of p53, P16, Proliferating cell nuclear antigen (PCNA) protein and estrogen receptor(ER) in human colorectal carcinoma(CRC), the relation between the expression of them and tumor clinicopathological characteristics, the relation between the expression of ER and the expression anti-oncogene, the role and clinical significance of estrogen in the proliferation of CRC.Methods: An immunohistochemical assay for p53, PCNA protein and ER was performed on paraffin sections from 148 colorectal carcinoma specimens. Meanwhile, the expression of ER and PCNA protein were examined immunohistochemically in 30 cases of normal colorectal mucosa specimens. 148 patients of CRC included 131 cases of adenocarcinoma and 17cases of Mucoid adenocarcinoma, 30 cases of normal colorectal mucosa (NCM) specimens were respectively obtained from 17 cases of the procedure for prolapse and hemorrhoids(PPH) surgical rectal mucosa specimens, 13 cases of constipation surgical colonic mucosa specimens. All cases were female patients.Results:1. The expression of ER in 148 cases of CRC was detected in 55.4%(82/148), there were the expression of ER in both adenocarcinoma and mucoid adenocarcinoma, ER immunoreactivity was always in nuclear. Conversely, there was not the expression of ER in 30 cases of NCM specimens (0/30) .The expression of ER was significantly higher in CRC than in NCM (P<0.01) .2. The expression of ER in post-menopausal group in 148 cases of CRC was significantly higher than in non-menopausal group (60.7% vs 38.9%, P<0.05). The expression of ER in hysteromyoma group in 148 cases of CRC was significantly higher than in non-hysteromyoma group (80.5% vs 47.3 %, P<0.05) . The expression of ER was detected in 71.8 % in higher histological differentiation group, 53.1 % in middle histological differentiation group, 23.1% in lower histological differentiation group, there was significant differences among three groups (P<0.05 ). While, there was not significant differences between tumor the expression of ER and patient age, tumor location, histological type, lymph nodal metastases, Dukes'stage (P>0.05) .3. The positive expression of Mutant p53 protein in 148 cases of CRC was detected in 77.7%(115/148). there was no significant differences between the expression of Mutant p53 protein and patient age, menopausal statu, hysteromyoma, tumor location, histological type, histological differentiation, lymph nodal metastases, Dukes' stage.4. The expression of ER in 148 cases of PCNA protein was detected in 92.6%(137/148) , while, there was not the expression of PCNA protein in 30 cases of NCM specimens (0/30) . The expression of PCNA protein was significantly higher in CRC than in NCM (P<0.01) .5. there was no significant differences between the expression of PCNA protein in 148 cases of CRC and patient age, menopausal statu, hysteromyoma, tumor location, histological type, histological differentiation, lymph nodalmetastases, Dukes' stage.6. There was not significant correlation between the expressin grading of ERand p53 protein(r=0.038f P>0.05).There was significant positive correlationbetween the expressin grading of ER and PCNA protein (r=0.242, P<0.01) .Conclusions: 1. Estrogen may play an important role of acceleratingproliferation in the occurrence and development of CRC. The part of CRC maybebelong to estrogen-dependent carcinoma, Antiestrogen therapy is probably effectivefor them. Examination of ER in CRC is the basis of endocrine therapy. 2. Result ofExaminating ER in CRC can demonstrate histological differentiation degree. 3. Theexpressin of ER was not associated with the expressin of Mutant p53 protein, thatgenerally exists in CRC.